Integrase inhibitor drugs during pregnancy and congenital anomalies: A case/non‐case study from the global pharmacovigilance database VigiBase®
Abstract In 2018, a significant neural tube defects (NTD) signal was reported after pre‐conceptional exposure to dolutegravir, but was not confirmed in further analysis. Since 2019, dolutegravir‐based regimen, an integrase inhibitor (INI), is recommended by WHO as the most‐effective first‐line thera...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
Wiley,
2024-08-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
| Call Number: |
A1234.567 |
|---|---|
| Copy 1 | Available |